Table 4.
AHP priority | Rank-based priority | AHP-Rank priority difference | Spearman’s coefficient of correlation | |||||
---|---|---|---|---|---|---|---|---|
n = 484 | ||||||||
| ||||||||
Major Criteria | Mean | 95% CI | Mean | 95% CI | Mean | 95% CI | rho | 95% CI |
| ||||||||
Prevent Cancer | 0.55 | 0.53 – 0.56 | 0.48 | 0.48 – 0.49 | 0.061 | 0.05 to 0.07 | 0.55 | 0.49 – 0.61 |
Minimize Side Effects | 0.17 | 0.16 – 0.18 | 0.20 | 0.19 – 0.21 | −0.028 | −0.03 to −0.02 | 0.89 | 0.87 – 0.91 |
Avoid False Positives | 0.15 | 0.14 – 0.16 | 0.17 | 0.16 – 0.18 | −0.019 | −0.023 to −0.015 | 0.91 | 0.89 – 0.93 |
Logistical considerations | 0.14 | 0.13 – 0.15 | 0.15 | 0.14 – 0.16 | −0.013 | −0.017 to −0.01 | 0.88 | 0.86 – 0.90 |
Subcriteria | ||||||||
Screening frequency | 0.32 | 0.30 – 0.34 | 0.35 | 0.33 – 0.37 | 0.076 | 0.069 to 0.083 | 0.92 | 0.91 – 0.94 |
Preparation for screening | 0.25 | 0.23 – 0.26 | 0.27 | 0.25 – 0.28 | 0.056 | 0.052 to 0.06 | 0.87 | 0.85 – 0.89 |
Screening procedure | 0.43 | 0.41 – 0.45 | 0.39 | 0.37 – 0.41 | 0.08 | 0.075 to 0.086 | 0.86 | 0.84 – 0.88 |